Ahead of the curve: Parkinson s Disease 101. Luisa Solis-Cohen, MD Movement Disorders Specialist Colorado Neurodiagnostics Littleton, CO
|
|
- Myron George
- 5 years ago
- Views:
Transcription
1 Ahead of the curve: Parkinson s Disease 101 Luisa Solis-Cohen, MD Movement Disorders Specialist Colorado Neurodiagnostics Littleton, CO
2 Our goals for discussion Recognize the motor symptoms of Parkinson s disease (PD) 2. Review the non-motor symptoms of PD 3. Discuss what is known about the underlying cause of PD 4. Discuss possible diagnostic tests 5. Learn about available medical and surgical therapies 6. Highlight recently approved therapies and future treatments 7. Connect you with ways to get involved and/or obtain further information
3 The many faces of Parkinson s disease.
4 Parkinson s disease is NOT uncommon.
5 What is Parkinson s disease? Progressive, neurodegenerative disorder affecting the body s ability to move fluidly. Motor symptoms Non-motor symptoms Dopamine dysfunction in the brain
6 Motor Symptoms 1. Bradykinesia 2. Tremor 3. Rigidity +/- Postural instability
7 Bradykinesia = slow movement The DEFINING feature of Parkinson s disease. Often described as weakness, clumsiness, incoordination. Here are some of the ways it affects voluntary and automated movements:
8 Tremor in Parkinson s disease Classically starts on one hand or leg Most prominent at rest Particularly bothersome if Dominant hand Action tremor also present Limits one s ability to fall asleep
9 Rigidity = stiffness Reaching across the body Getting out of a car or chair Turning over or repositioning in bed
10 Motor Symptoms 1. Bradykinesia 2. Tremor 3. Rigidity +/- Postural instability
11 Gait Dynamics Stooped posture Reduced arm swing Shuffling stride Freezing Unwanted accelerations Postural instability & tendency to fall +/- Tremor
12 Other motor symptoms... Dystonia: cramping and posturing due to involuntary muscle twisting and contraction despite being at rest. Dyskinesia: uncontrolled, involuntary movement. Commonly regarded as wiggling, head bobbing and fidgeting.
13 Our goals for discussion Recognize the motor symptoms of Parkinson s disease (PD) 2. Review the non-motor symptoms of PD 3. Discuss what is known about the underlying cause of PD 4. Discuss possible diagnostic tests 5. Learn about available medical and surgical therapies 6. Highlight recently approved therapies and future treatments 7. Connect you with ways to get involved and/or obtain further information
14 Non-motor symptoms Loss of sense of smell Constipation REM Sleep Disorder Anxiety and/or depression Mood changes Impulsivity Apathy Fatigue Bladder habit changes Restless legs syndrome Cognitive issues memory difficulties, slowed thinking, confusion Vision changes Orthostatic hypotension Sexual problems Drooling Skin changes Excessive sweating Pain
15 Our goals for discussion Recognize the motor symptoms of Parkinson s disease (PD) 2. Review the non-motor symptoms of PD 3. Discuss what is known about the underlying cause of PD 4. Discuss possible diagnostic tests 5. Learn about available medical and surgical therapies 6. Highlight recently approved therapies and future treatments 7. Connect you with ways to get involved and/or obtain further information
16 What causes Parkinson s disease?
17 Alpha-synuclein plays a role in Parkinson s disease Alpha-synuclein is a normal protein we all have. Likely plays a role in cell to cell communication. Overabundant and/or misfolded in Parkinson s leading to certain genetic forms of PD and L ewy Bodies. A H O T T O PI C in PD research. Alpha-synuclein antibody therapy is being studied.
18 Braak Hypothesis Braak, Heiko; Tredici, Kelly Del; Rüb, Udo; Vos, Rob A. I. de; Steur, Ernst N. H. Jansen; Braak, Eva ( ). "Staging of brain pathology related to sporadic Parkinson s disease". Neurobiology of Aging. 24 (2):
19
20 Does Parkinson s originate in the gut? - Truncal vagotomy trends towards decreased likelihood of Parkinson s disease - Bacteria populating the gut appears to be different in people with Parkinson s disease, but poor consistency between studies - Constipation often precedes motor symptoms - Alpha synuclein found in enteric nervous system No conclusions yet! Keep your eyes on the gut!
21 Barreto et al. Front. Aging Neurosci., 09 January 2015
22 Our goals for discussion Recognize the motor symptoms of Parkinson s disease (PD) 2. Review the non-motor symptoms of PD 3. Discuss what is known about the underlying cause of PD 4. Discuss possible diagnostic tests 5. Learn about available medical and surgical therapies 6. Highlight recently approved therapies and future treatments 7. Connect you with ways to get involved and/or obtain further information
23 How did my doctor make the diagnosis of PD? Do I need further testing? Diagnosis is made based on a clinical examination (bradykinesia, rigidity, tremor). M R I is N O T necessary for the diagnosis, but may be obtained in certain individuals, especially if the pattern of symptoms atypical. M R I brain imaging is often normal. Genetic testing is offers limited additional information, but can be beneficial in young onset Parkinsonism. D at scan looks at dopamine transport in the brain, but is not specific to Parkinson s disease.
24 DaT Scan (Dopamine transporter scan) Most helpful in distinguishing Parkinson s disease from essential tremor or drug induced Parkinson s disease. Not specific to Parkinson s disease. Does not distinguish PD from some forms of Parkinsonism such as PSP, MSA, etc. FDA approved 2011 Small amount of radioactive material used Determines amount of dopamine in brain
25 Our goals for discussion Recognize the motor symptoms of Parkinson s disease (PD) 2. Review the non-motor symptoms of PD 3. Discuss what is known about the underlying cause of PD 4. Discuss possible diagnostic tests 5. Learn about available medical and surgical therapies 6. Highlight recently approved therapies and future treatments 7. Connect you with ways to get involved and/or obtain further information
26 Symptomatic Treatment of Parkinson s disease treat symptoms by directly or indirectly compensating for loss of dopamine Carbidopa/levodopa (Sinemet), pramipexole (Mirapex), etc. Exercise Disease modifying Slow ongoing loss of dopamine-producing brain cells among others Neuroprotective Prevents loss of dopaminergic neurons. Restorative Replace lost cells or connections Stem cells, growth factors, gene therapy
27 Everyone should exercise! Overall well being Heart and bone health Motor symptoms improve Coordination, gait/balance, stiffness Non-motor symptoms improve improve mood & sleep lessen constipation Best exercise? Yoga and Tai Chi - Balance Dancing - Coordination Boxing Swimming Cycling Golf Best exercise is the one you will stick with!
28
29 Individualized plan Patient goals Treatment considerations... Minimize falls and other health risks Feasibility of therapy (dosing, cost, transportation ) Age of patient, social dynamics, other medical issues, medication interactions Non-motor symptoms Need for advanced therapies Timing of therapy initiation Rehabilitative services are integral PT, OT, S&S, Lee Silverman Voice Training (BIG and LOUD) Social support systems
30 Medications for Motor Symptoms Levodopa C arbidopa/levodopa I R /C R ( Sinemet) C arbidopa/levodopa E R ( R ytary) C arbidopa/levodopa intestinal gel infusion ( D uopa) Orally disintegrating tablets ( Parcopa) C arbidopa/levodopa/entacapone ( Stalevo) D opamine agonists Apomorphine ( Apokyn) Pramipexole I R /E R ( M irapex) Ropinirole IR/XL (Requip) R otigotine patch ( N eupro) Bromocriptine ( Parlodel) MAO-B inhibitors Rasagiline (Azilect) Selegiline ( D eprenyl) Fast dissolving selegiline ( Zelepar) Safinamide ( X adago) COMT inhibitors E ntacapone ( C omtan) T olcapone ( T asmar) Anticholinergic T rihexyphenidyl ( Artane) Benztropine ( C ogentin) Other ( multiple mechanisms) Amantadine ( Symmetrel) Amantadine E R ( G ocovri) Amantadine E R ( Osmolex)
31 Non-motor symptom management Loss of sense of smell C onstipation R E M Sleep D isorder Anxiety and/or depression M ood changes I mpulsivity Apathy Fatigue Bladder habit changes R estless legs syndrome Cognitive issues memory difficulties, slowed thinking, confusion V ision changes Orthostatic hypotension Sexual problems D rooling Skin changes E xcessive sweating Pain
32 Parkinson s treatment, more than just a pill panini?
33 Maximizing the Benefits of your Medications Optimize your doctor s understanding of your goals, your bothersome symptoms and their response to medications. Document and bring to clinic! Journal, spreadsheet, calendar, graph. 2. Be honest about your real medication schedule and dosing at home! 3. Take doses on time 4. To eat or not to eat with your levodopa?
34 Motor fluctuations
35 Advanced therapies.
36 Deep Brain Stimulation (DBS) High frequency electrical stimulation of brain structures by electrodes surgically implanted deep inside the brain Mechanism of action: Disrupt the disruption FDA approved for Tremor 1997 Parkinson s disease 2002 Dystonia 2003 (HDE) Obsessive C ompulsive disorder 2009 ( H DE ) Over 150,000 individuals with DBS implanted worldwide, >⅔ with PD Okun, M. S. (2012). Deep-Brain Stimulation for Parkinson's Disease. New England Journal of Medicine, 367(16),
37 Who can benefit from DBS therapy? Majority: PD symptoms for at least 4 years Motor fluctuations, with or without dyskinesias Levodopa offers a good response for at least part of the day Combinations of PD meds were tried without substantial improvement Minority: Medication-resistant tremor Bothersome dystonia PD medications are poorly tolerated at doses need to treat motor symptoms Significant implications to professional life
38 Smoothing out motor fluctuations Decrease off time Increased on time without bothersome dyskinesias Hickey P, Stacy M. Deep Brain Stimulation: A Paradigm Shifting Approach to Treat Parkinson s Disease. Frontiers in Neuroscience. 2016;10:173.
39 When is DBS surgery not recommended? Atypical Parkinsonism Primary motor symptoms of concern are not levodopa responsive (can exclude tremor) Psychiatric illness Psychosis Severe depression Dementia Other serious health conditions
40 DBS is a Team Approach Movement Disorders Neurologist Confirm PD diagnosis / Levodopa on-off evaluations / Medication optimization Discuss expectations and limitations with DBS therapy. Discuss DBS system options and neural targets. DBS programming Neurosurgeon Surgical candidacy consultation Discuss neurosurgical options and DBS systems DBS surgery itself: typically in 2 stages. Battery replacements Neuropsychologist Cognitive evaluation Psychiatrist, social worker, PCP, PT, OT, SLP
41 The DBS electrode is composed of several contacts.
42 DBS electrode generates a precise region of stimulation within the intended brain target.
43 Medtroni c Three FDA Approved DBS Systems Boston Scientific Abbott/SJM Images courtesy of Medtronic, Abbott and Boston
44 Levodopa Intestinal Gel Infusion (Duopa) FDA approved Jan 2015 Carbidopa/levodopa suspension is delivered continuously into the intestine for up to 16 hours Smooths out motor fluctuations (decreased off time, increased on time without dyskinesias). Some patients no longer take oral medications. Images from Abbvie Inc.
45 Our goals for discussion Recognize the motor symptoms of Parkinson s disease (PD) 2. Review the non-motor symptoms of PD 3. Discuss what is known about the underlying cause of PD 4. Learn about available medical and surgical therapies 5. Highlight recently approved therapies and future treatments 6. Connect you with ways to get involved and/or obtain further information
46 Recent approvals... March 21, clinical trials adjunct therapy to carbidopa/levodopa Mechanisms of action include blocking the enzyme monoamine oxidase B (more available dopamine), blocking sodium and potassium channels and reducing glutamate release Reduce off time Increase on time without dyskinesias Restrictions and a number of drug-drug interactions There are a number of other FDA approved MAO-B inhibitors. No head to head trials. Which is best?
47 Recent approvals... August 24, 2017 Reduction of time with bothersome dyskinesias 25-30% compared to placebo. R eduction of daily off time by approximately 1 hr per day. Studies compare placebo to amantadine E R. N o comparison to amantadine H C l.
48 Neuroprotection Israpidine Inosine In the Pipeline... H igh blood pressure medication. Potential for less oxidative stress and possibly less damage to dopaminergic neurons. Phase III STEADY-PD trial ongoing, estimated completion by mid 2019 D rug that elevates blood uric acid level ( higher in those with gout and some kidney stones) Phase III SURE-PD trial ongoing, estimated completion date Aug 2020 E xenatide Diabetes medication. Preclinical studies suggest a role in inhibiting cell death, reducing oxidative stress, enhancing mitochondria function, and promoting neuronal functioning Caffeine Nicotine U nclear if nicotine or another compotent of tobacco plays the integral role N ot permission to take up smoking
49 Neuroprotection in the Pipeline Anti - alpha-synuclein monoclonal antibody shown to be safe and tolerable phase 1 trials. O ngoing are 2 phase 2 trials looking at efficacy and safety of 2 such M ABs Pasadena and Spark trials. Both recruiting in D enver.
50 Alpha-synuclein plays a role in Parkinson s disease Alpha-synuclein is a normal protein we all have. Likely plays a role in cell to cell communication. Overabundant and/or misfolded in Parkinson s leading to certain genetic forms of PD and L ewy Bodies. A H O T T O PI C in PD research. Alpha-synuclein antibody therapy is being studied.
51 AAN Practice Parameter: Neuroprotection in Parkinson s Disease Levodopa does not accelerate disease progression N o treatment has been shown to be neuroprotective N o evidence that vitamin or food additives can improve motor function in PD
52 Potential future advanced therapies... High-frequency Focused Ultrasound In clinical trials for tremor (thalamotomy) and dyskinesia (pallidotomy) treatment FDA approved for essential tremor Unilateral lesions only Non-invasive, but permanent tissue destruction Closed-loop deep brain stimulation Stimulation is tailored in response to one s own neuronal activity Adapts to fluctuating symptoms and interpatient variability Potentially decreases side effects, decreases habituation, extends stimulator battery life
53 Our goals for discussion Recognize the motor symptoms of Parkinson s disease (PD) 2. Review the non-motor symptoms of PD 3. Discuss what is known about the underlying cause of PD 4. Learn about available medical and surgical therapies 5. Highlight recently approved therapies and future treatments 6. Connect you with ways to get involved and/or obtain further information
54 Clinical trial opportunities Fox Trial Finder: foxtrialfinder.michaeljfox.org National Institutes of Health: Educational, exercise & support group resources Parkinson Association of the Rockies Davis Phinney Foundation Parkinson s Foundation Aware in Care Kit or PD-INFO
55
56 Bonus slides
57 LRRK 2 (chromosome 12) Autosomal dominant I ncomplete penetrance ( ~50% develop PD by age 75%) 1-2% of all PD have this G 2019S mutation 5% of all familial PD 18% of all Ashkenazi Jews with PD 30% of all Ashkenazi Jews with PD 40% of all N. African Arabs with PD
58 Genetic testing for LRRK2 If parent has PD and NOT Ashkenazi Jewish: 2% of L R R K 2 mutation 50% penetrance by age 75 50% risk offspring inherits mutation R isk for offspring to inherit L R R K 2 mutation and get PD = 2% * 50%* 50% = 0.5% R isk for parent and another 1st degree relative and Ashkenazi Jewish = 30% of having mutation. R isk that off inheriting the mutation and get PD = 30% * 50% *50% = 7.5%
Optimizing Clinical Communication in Parkinson s Disease:
Optimizing Clinical Communication in Parkinson s Disease:,Strategies for improving communication between you and your neurologist PFNCA Symposium March 25, 2017 Pritha Ghosh, MD Assistant Professor of
More informationScott J Sherman MD, PhD The University of Arizona PARKINSON DISEASE
Scott J Sherman MD, PhD The University of Arizona PARKINSON DISEASE LEARNING OBJECTIVES The Course Participant will: 1. Be familiar with the pathogenesis of Parkinson s Disease (PD) 2. Understand clinical
More informationTreatment of Parkinson s Disease: Present and Future
Treatment of Parkinson s Disease: Present and Future Karen Blindauer, MD Professor of Neurology Director of Movement Disorders Program Medical College of Wisconsin Neuropathology: Loss of Dopamine- Producing
More informationMedication Management & Strategies When the levodopa honeymoon is over
Medication Management & Strategies When the levodopa honeymoon is over Eric J Pappert, MD Parkinson s Disease & Movement Disorders Center Neurology Associates Medication Options in Parkinson s Carbidopa/Levodopa
More informationWelcome and Introductions
Parkinson s Disease Spotlight on Treatment Advances Tuesday, January 26, 2016 Welcome and Introductions Stephanie Paul Vice President Development and Marketing American Parkinson Disease Association 1
More informationParkinson Disease. Lorraine Kalia, MD, PhD, FRCPC. Presented by: Ontario s Geriatric Steering Committee
Parkinson Disease Lorraine Kalia, MD, PhD, FRCPC Key Learnings Parkinson Disease (L. Kalia) Key Learnings Parkinson disease is the most common but not the only cause of parkinsonism Parkinson disease is
More informationCommunicating About OFF Episodes With Your Doctor
Communicating About OFF Episodes With Your Doctor Early in Parkinson s disease (PD), treatment with levodopa and other anti-pd drugs provides continuous benefit. As the disease progresses, however, symptom
More informationWelcome and Introductions
Parkinson s Disease Spotlight on Addressing Motor and Non-Motor Symptoms The Changing Landscape Wednesday, March 8, 2017 Welcome and Introductions Stephanie Paul Vice President Development and Marketing
More informationParkinson s Disease Update. Presented by Joanna O Leary, MD Movement disorder neurologist Providence St. Vincent s
Parkinson s Disease Update Presented by Joanna O Leary, MD Movement disorder neurologist Providence St. Vincent s What is a movement disorder? Neurological disorders that affect ability to move by causing
More informationKey Concepts and Issues in Parkinson s Disease in 2016
Key Concepts and Issues in Parkinson s Disease in 2016 Michael Rezak, M.D., Ph.D. Section Chief, Neurosciences Institute Director, Movement Disorders and Neurodegenerative Diseases Center Northwestern
More informationBest Medical Treatments for Parkinson s disease
Best Medical Treatments for Parkinson s disease Bernadette Schöneburg, M.D. June 20 th, 2015 What is Parkinson s Disease (PD)? Progressive neurologic disorder that results from the loss of specific cells
More informationObjectives. Emerging Treatments in Parkinson s s Disease. Pathology. As Parkinson s progresses it eventually affects large portions of the brain.
Objectives Emerging Treatments in Parkinson s s Disease 1) Describe recent developments in the therapies for Parkinson s Disease Jeff Kraakevik MD Assistant Professor OHSU/Portland VAMC Parkinson s Center
More informationParkinson's Disease KP Update
Parkinson's Disease KP Update Andrew Imbus, PA-C Neurology, Movement Disorders Kaiser Permanente, Los Angeles Medical Center No disclosures "I often say now I don't have any choice whether or not I have
More informationEvaluation of Parkinson s Patients and Primary Care Providers
Evaluation of Parkinson s Patients and Primary Care Providers 2018 Movement Disorders Half Day Symposium Elise Anderson MD Medical Co-Director, PBSI Movement Disorders 6/28/2018 1 Disclosures GE Speaker,
More informationPresented by Meagan Koepnick, Josh McDonald, Abby Narayan, Jared Szabo Mentored by Dr. Doorn
Presented by Meagan Koepnick, Josh McDonald, Abby Narayan, Jared Szabo Mentored by Dr. Doorn Objectives What agents do we currently have available and what do we ideally need? What biomarkers exist for
More informationPARKINSON S DISEASE. Nigrostriatal Dopaminergic Neurons 5/11/16 CARDINAL FEATURES OF PARKINSON S DISEASE. Parkinson s disease
5/11/16 PARKINSON S DISEASE Parkinson s disease Prevalence increases with age (starts 40s60s) Seen in all ethnic groups, M:F about 1.5:1 Second most common neurodegenerative disease Genetics role greater
More informationWHAT DEFINES YOPD? HANDLING UNIQUE CONCERNS REBECCA GILBERT, MD, PHD VICE PRESIDENT, CHIEF SCIENTIFIC OFFICER, APDA MARCH 14, 2019
WHAT DEFINES YOPD? HANDLING UNIQUE CONCERNS REBECCA GILBERT, MD, PHD VICE PRESIDENT, CHIEF SCIENTIFIC OFFICER, APDA MARCH 14, 2019 YOUNG ONSET PARKINSON S DISEASE Definition: Parkinson s disease diagnosed
More informationPharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Assistant Professor of Neurology
+ Pharmacologic Treatment of Parkinson s Disease Nicholas J. Silvestri, M.D. Assistant Professor of Neurology + Overview n Brief review of Parkinson s disease (PD) n Clinical manifestations n Pathophysiology
More informationParkinson s Disease Update
Parkinson s Disease Update Elise Anderson MD Providence Center for Parkinson s Disease October 26, 2017 11/6/2017 1 Disclosures GE Speaker, DaTSCAN 11/6/2017 2 Outline PD diagnosis Motor and nonmotor symptoms
More informationWhat is Parkinson s Disease?
2018 Update in Parkinson s Disease: Treatments and Future Plans Arita McCoy, MSN, CRNP Johns Hopkins Parkinson s Disease and Movement Disorder Center A National Parkinson Foundation Center of Excellence
More information10th Medicine Review Course st July Prakash Kumar
10th Medicine Review Course 2018 21 st July 2018 Drug Therapy for Parkinson's disease Prakash Kumar National Neuroscience Institute Singapore General Hospital Sengkang General Hospital Singhealth Duke-NUS
More informationPharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Associate Professor of Neurology
+ Pharmacologic Treatment of Parkinson s Disease Nicholas J. Silvestri, M.D. Associate Professor of Neurology + Disclosures n NO SIGNIFICANT FINANCIAL, GENERAL, OR OBLIGATION INTERESTS TO REPORT + Learning
More informationParkinson s Disease. Prevalence. Mark S. Baron, M.D. Cardinal Features. Clinical Characteristics. Not Just a Movement Disorder
Prevalence Parkinson s Disease Mark S. Baron, M.D. Associate Professor of Neurology Movement Disorders Section VCU School of Medicine Common disorder Approaching 1% by 65 yrs of age, 2% by 80 yrs of age
More informationWhat s new for diagnosing and treating Parkinson s Disease?
What s new for diagnosing and treating Parkinson s Disease? Erika Driver-Dunckley, MD Associate Professor of Neurology Program Director Movement Disorders Fellowship Assistant Program Director Neurology
More informationThe symptoms of the Parkinson s disease may vary from person to person. The symptoms might include the following:
1 PARKINSON S DISEASE Parkinson's disease is a long term disease related to the central nervous system that mainly affects the motor system, resulting in the loss of dopamine, which helps in producing
More informationMotor Fluctuations Stephen Grill, MD, PHD Parkinson s and Movement Disorders Center of Maryland and Johns Hopkins University
Motor Fluctuations Stephen Grill, MD, PHD Parkinson s and Movement Disorders Center of Maryland and Johns Hopkins University I have no financial interest with any entity producing marketing, re-selling,
More informationOverview. Overview. Parkinson s disease. Secondary Parkinsonism. Parkinsonism: Motor symptoms associated with impairment in basal ganglia circuits
Overview Overview Parkinsonism: Motor symptoms associated with impairment in basal ganglia circuits The differential diagnosis of Parkinson s disease Primary vs. Secondary Parkinsonism Proteinopathies:
More informationParkinson s Disease Medications: Professionals Edition
Parkinson s Disease Clinic and Research Center University of California, San Francisco 505 Parnassus Ave., Rm. 795-M, Box 0114 San Francisco, CA 94143-0114 (415) 476-9276 http://pdcenter.neurology.ucsf.edu
More informationParkinson s Disease Update. Colleen Peach, RN, MSN, FNP Movement Disorders Clinic Emory University School of Medicine March 7, 2015
Parkinson s Disease Update Colleen Peach, RN, MSN, FNP Movement Disorders Clinic Emory University School of Medicine March 7, 2015 Parkinson s Disease Progressive, chronic, neurodegenerative disease Slow,
More informationParkinson s Disease WHERE HAVE WE BEEN, WHERE ARE WE HEADING? CHARLECE HUGHES D.O.
Parkinson s Disease WHERE HAVE WE BEEN, WHERE ARE WE HEADING? CHARLECE HUGHES D.O. Parkinson s Epidemiology AFFECTS 1% OF POPULATION OVER 65 MEAN AGE OF ONSET 65 MEN:WOMEN 1.5:1 IDIOPATHIC:HEREDITARY 90:10
More informationMedications used to treat Parkinson s disease
Medications used to treat Parkinson s disease Edwin B. George, M.D., Ph.D. Director of Wayne State University Movement Disorder Clinic University Health Center Neurology Clinic University Health The John
More informationUnderstanding Parkinson s Disease Important information for you and your loved ones
Patient Education Understanding Parkinson s Disease Important information for you and your loved ones This handout explains the signs, symptoms, and possible treatments of Parkinson s disease. Parkinson
More informationProgram Highlights. Michael Pourfar, MD Co-Director, Center for Neuromodulation New York University Langone Medical Center New York, New York
Program Highlights David Swope, MD Associate Professor of Neurology Mount Sinai Health System New York, New York Michael Pourfar, MD Co-Director, Center for Neuromodulation New York University Langone
More informationSurgical Management of Parkinson s Disease
Surgical Management of Parkinson s Disease Shyamal H. Mehta MD, PhD Assistant Professor of Neurology, Movement Disorders Division Mayo Clinic College of Medicine Mayo Clinic, Arizona 2016 MFMER slide-1
More informationparts of the gastrointenstinal tract. At the end of April 2008, it was temporarily withdrawn from the US Market because of problems related to
parts of the gastrointenstinal tract. At the end of April 2008, it was temporarily withdrawn from the US Market because of problems related to crystallization of the drug, which caused unreliable drug
More informationPARKINS ON CENTER. Parkinson s Disease: Diagnosis and Management. Learning Objectives: Recognition of PD OHSU. Disclosure Information
OHSU PARKINS ON CENTER Parkinson s Disease: Diagnosis and Management for Every MD Disclosure Information Grants/Research Support: National Parkinson Foundation, NIH, Michael J. Fox Foundation Consultant:
More informationFaculty. Joseph Friedman, MD
Faculty Claire Henchcliffe, MD, DPhil Associate Professor of Neurology Weill Cornell Medical College Associate Attending Neurologist New York-Presbyterian Hospital Director of the Parkinson s Institute
More informationParkinson s Disease Current Treatment Options
Parkinson s Disease Current Treatment Options Daniel Kassicieh, D.O., FAAN Sarasota Neurology, P.A. PD: A Chronic Neurodegenerative Ds. 1 Million in USA Epidemiology 50,000 New Cases per Year Majority
More informationPD ExpertBriefings: Parkinson s Medications: Today and Tomorrow Led By: Cynthia L. Comella, M.D., F.A.A.N.
PD ExpertBriefings: Parkinson s Medications: Today and Tomorrow Led By: Cynthia L. Comella, M.D., F.A.A.N. To hear the session live on: Tuesday, April 17, 2012 at 1:00 PM ET. DIAL: 1 (888) 272-8710 and
More informationEvaluation and Management of Parkinson s Disease in the Older Patient
Evaluation and Management of Parkinson s Disease in the Older Patient David A. Hinkle, MD, PhD Comprehensive Movement Disorders Clinic Pittsburgh Institute for Neurodegenerative Diseases University of
More informationPD: Key Treatment Considerations
PD: Key Treatment Considerations 2018 Management of Neurologic and Neurosurgical Disorders in Daily Practice Elise Anderson MD Medical Co-Director, PBSI Movement Disorders 11/27/2018 1 Outline Treatment
More informationPARKINSON S MEDICATION
PARKINSON S MEDICATION History 1940 50 s Neurosurgeons operated on basal ganglia. Improved symptoms. 12% mortality 1960 s: Researchers identified low levels of dopamine caused Parkinson s leading to development
More informationIssues for Patient Discussion
onmotor complications radykinesia Screening Tools asked PD micrographia eurodegeneration Designed for Use by Family Practitioners remor on-off opamine agonists tiffness depression ostural instability wearing
More informationAdvances in Parkinson s Disease Treatment. Ryan J. Uitti, M.D. Professor of Neurology Mayo Clinic, Jacksonville, FL
Advances in Parkinson s Disease Treatment Ryan J. Uitti, M.D. Professor of Neurology Mayo Clinic, Jacksonville, FL Uitti.ryan@mayo.edu Ryan J. Uitti, MD Disclosure receives research support from NIH/NINDS,
More informationParkinson s disease Therapeutic strategies. Surat Tanprawate, MD Division of Neurology University of Chiang Mai
Parkinson s disease Therapeutic strategies Surat Tanprawate, MD Division of Neurology University of Chiang Mai 1 Scope Modality of treatment Pathophysiology of PD and dopamine metabolism Drugs Are there
More informationWELCOME. Parkinson s 101 for the Newly Diagnosed. Today s Topic: Parkinson s Basics presented by Cari Friedman, LCSW
WELCOME Parkinson s 101 for the Newly Diagnosed Today s Topic: Parkinson s Basics presented by Cari Friedman, LCSW Parkinson s Disease 101 Presenter for Today Cari Friedman, LCSW Patient and Family Service
More information05-Nov-15. Impact of Parkinson s Disease in Australia. The Nature of Parkinson s disease 21st Century
Peter Silburn Professor Clinical Neuroscience University of Queensland Queensland Brain Institute Neurosciences Queensland Impact of in Australia Second most common neurodegenerative disorder Up to 64,000
More informationEXPLORING OPPORTUNITIES TO PARTNER TOWARD CURES FOR PD. Chicago Clinical Research Fair June 11, 2016
EXPLORING OPPORTUNITIES TO PARTNER TOWARD CURES FOR PD Chicago Clinical Research Fair June 11, 2016 HOW DO WE LEARN MORE ABOUT PARKINSON S DISEASE? Patient-reported data Diagnosis and clinical symptoms
More informationThe PD You Don t See: Cognitive and Non-motor Symptoms
The PD You Don t See: Cognitive and Non-motor Symptoms Benzi M. Kluger, M.D., M.S. Associate Professor of Neurology and Psychiatry Director Movement Disorders Center University of Colorado Denver Goals
More informationCardinal Features of Parkinson s. Management of Parkinson s Disease. Drug Induced Parkinson s. Other Parkinson s Symptoms.
Cardinal Features of Parkinson s Management of Parkinson s Disease Kristin S. Meyer, PharmD, CGP, FASHP Assistant Professor of Pharmacy Practice Drake University & Iowa Veterans Home Spring 2009 Tremor
More informationRecent Advances in the cause and treatment of Parkinson disease. Anthony Schapira Head of Dept. Clinical Neurosciences UCL Institute of Neurology UCL
Recent Advances in the cause and treatment of Parkinson disease Anthony Schapira Head of Dept. Clinical Neurosciences UCL Institute of Neurology UCL SOME BACKGROUND incidence rate (per 100.000 person years)
More informationParkinson Disease Treatment Research Pipeline Codrin Lungu MD Program Director, Office of Clinical Research Staff Clinician, Office of the Clinical
Parkinson Disease Treatment Research Pipeline Codrin Lungu MD Program Director, Office of Clinical Research Staff Clinician, Office of the Clinical Director NINDS, NIH Disclosures I receive payments from
More information2/20/18. History of Parkinson s. What is happening in the brain? DOPAMINE! Epidemiology. Parkinson s Disease. It s much more than tremor
Parkinson s Disease History of Parkinson s It s much more than tremor Laura Dixon, DNP, MPA, APRN, FNP-BC University of Louisville Department of Neurology Movement Disorders Division Parkinson s Disease
More informationMAXIMIZING FUNCTION IN PARKINSON S DISEASE
1 MAXIMIZING FUNCTION IN PARKINSON S DISEASE September 13, 2016 End Falls This Falls Conference Jan Goldstein Elman One Step Ahead Mobility Toronto, Ontario Outline An overview of Parkinson s disease (PD):
More informationPrior Authorization with Quantity Limit Program Summary
Gocovri (amantadine) Prior Authorization with Quantity Limit Program Summary This prior authorization applies to Commercial, NetResults A series, SourceRx and Health Insurance Marketplace formularies.
More informationMovement Disorders: A Brief Overview
Movement Disorders: A Brief Overview Albert Hung, MD, PhD Massachusetts General Hospital Harvard Medical School August 17, 2006 Cardinal Features of Parkinsonism Tremor Rigidity Bradykinesia Postural imbalance
More information9/26/18. Objectives. Disclosures. Parkinson s Disease Update Clinical and Operational Considerations
Parkinson s Disease Update Clinical and Operational Considerations Dana Saffel, PharmD, BCGP, CPh, FASCP President, CEO PharmaCare Strategies, Inc. September 2018 Objectives Describe epidemiology and pathophysiology
More informationParkinson s Disease. Sirilak yimcharoen
Parkinson s Disease Sirilak yimcharoen EPIDEMIOLOGY ~1% of people over 55 years Age range 35 85 years peak age of onset is in the early 60s ~5% of cases characterized by an earlier age of onset (typically
More informationPharmacy Coverage Guidelines are subject to change as new information becomes available.
ZELAPAR (selegiline hydrochloride) orally disintegrating tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific
More informationParkinson s Disease: initial diagnosis, initial treatment & non-motor features. J. Timothy Greenamyre, MD, PhD
Parkinson s Disease: initial diagnosis, initial treatment & non-motor features J. Timothy Greenamyre, MD, PhD Involuntary tremulous motion, with lessened muscular power, in parts not in action and even
More informationIII./3.1. Movement disorders with akinetic rigid symptoms
III./3.1. Movement disorders with akinetic rigid symptoms III./3.1.1. Parkinson s disease Parkinson s disease (PD) is the second most common neurodegenerative disorder worldwide after Alzheimer s disease.
More information8/28/2017. Behind the Scenes of Parkinson s Disease
BEHIND THE SCENCES IN Parkinson s Disease Behind the Scenes of Parkinson s Disease Anna Marie Wellins DNP, ANP C Objectives Describe prevalence of Parkinson's disease (PD) Describe the hallmark pathologic
More informationSubthalamic Nucleus Deep Brain Stimulation (STN-DBS)
Subthalamic Nucleus Deep Brain Stimulation (STN-DBS) A Neurosurgical Treatment for Parkinson s Disease Parkinson s Disease Parkinson s disease is a common neurodegenerative disorder that affects about
More informationThe PD You Don t See: Cognitive and Non-motor Symptoms
The PD You Don t See: Cognitive and Non-motor Symptoms Benzi M. Kluger, M.D., M.S. Assistant Professor of Neurology and Psychiatry University of Colorado Denver Goals 1) What are the most common non-motor
More informationTHIS IS NOT YOUR GRANDMOTHER S DISEASE: WHAT DOES BEING DIAGNOSED WITH PARKINSON S DISEASE MEAN TODAY?
THIS IS NOT YOUR GRANDMOTHER S DISEASE: WHAT DOES BEING DIAGNOSED WITH PARKINSON S DISEASE MEAN TODAY? THURSDAY MARCH 14, 2019 REBECCA GILBERT, MD, PHD VICE PRESIDENT, CHIEF SCIENTIFIC OFFICER, APDA AMERICAN
More informationEMERGING TREATMENTS FOR PARKINSON S DISEASE
EMERGING TREATMENTS FOR PARKINSON S DISEASE Katerina Markopoulou, MD, PhD Director Neurodegenerative Diseases Program Department of Neurology NorthShore University HealthSystem Clinical Assistant Professor
More informationThe Shaking Palsy of 1817
The Shaking Palsy of 1817 A Treatment Update on Parkinson s Disease Dr Eitzaz Sadiq Neurologist CH Baragwanath Acadamic Hospital Parkinson s Disease O Premature death of dopaminergic neurons O Symptoms
More informationDeep Brain Stimulation: Indications and Ethical Applications
Deep Brain Stimulation Overview Kara D. Beasley, DO, MBe, FACOS Boulder Neurosurgical and Spine Associates (303) 562-1372 Deep Brain Stimulation: Indications and Ethical Applications Instrument of Change
More informationLet s Look at Parkinson s (PD) Sheena Morgan Parkinson s Disease Nurse Specialist Isle of Wight NHS Trust November 2016
Let s Look at Parkinson s (PD) Sheena Morgan Parkinson s Disease Nurse Specialist Isle of Wight NHS Trust November 2016 What is Parkinson s? Parkinson's is a progressive neurological condition. People
More informationPD ExpertBriefing: What s in the Parkinson s Pipeline
PD ExpertBriefing: What s in the Parkinson s Pipeline Presented by: David G. Standaert, M.D., Ph.D. Professor of Neurology Director, Center for Neurodegeneration and Experimental Therapeutics University
More informationAdvanced Therapies for Motor Symptoms in PD. Matthew Boyce MD
Advanced Therapies for Motor Symptoms in PD Matthew Boyce MD Medtronic Education Teva Speakers Bureau Acadia Speakers Bureau Disclosures Discuss issues in advanced PD Adjunct therapies to levo-dopa Newer
More informationHeadway Victoria Epilepsy and Parkinson s Centre
Headway Victoria Epilepsy and Parkinson s Centre Parkinson s Overview and Medication Shannon Oatway Community Education/ Awareness Coordinator What is Parkinson s Disease? The basics It is a chronic and
More informationParkinson s Disease An Open Doors Perspective
Parkinson s Disease An Open Doors Perspective MFP Transition Center Nurse Laura Bingell RN Open Doors is a Money Follows the Person program of New York Association on Independent Living under contract
More informationDr Barry Snow. Neurologist Auckland District Health Board
Dr Barry Snow Neurologist Auckland District Health Board Dystonia and Parkinson s disease Barry Snow Gowers 1888: Tetanoid chorea Dystonia a movement disorder characterized by sustained or intermittent
More informationParkinson s Disease. Gillian Sare
Parkinson s Disease Gillian Sare Outline Reminder about PD Parkinson s disease in the inpatient Surgical patients with PD Patients who cannot swallow End of life care Parkinson s disease PD is the second
More informationSection 1: What is Parkinson s? Parkinson's Disease Webinar 4/27/2012. April 27th, :00-1:00 PM EST
4/27/2012 Parkinson's Disease Webinar April 27th, 2012 12:00-1:00 PM EST Presenter: Jon Collins, Manager, Programs and Events, Parkinson Society Central & Northern Ontario Section 1: What is Parkinson
More informationPARKINSON S PRIMER. Dr. Kathryn Giles MD, MSc, FRCPC Cambridge, Ontario, Canada
PARKINSON S PRIMER Dr. Kathryn Giles MD, MSc, FRCPC Cambridge, Ontario, Canada COPYRIGHT 2017 BY SEA COURSES INC. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted
More informationParkinson s Disease Initial Clinical and Diagnostic Evaluation. J. Timothy Greenamyre, MD, PhD
Parkinson s Disease Initial Clinical and Diagnostic Evaluation J. Timothy Greenamyre, MD, PhD Involuntary tremulous motion, with lessened muscular power, in parts not in action and even when supported
More informationTreatment of Parkinson s Disease and of Spasticity. Satpal Singh Pharmacology and Toxicology 3223 JSMBS
Treatment of Parkinson s Disease and of Spasticity Satpal Singh Pharmacology and Toxicology 3223 JSMBS singhs@buffalo.edu 716-829-2453 1 Disclosures NO SIGNIFICANT FINANCIAL, GENERAL, OR OBLIGATION INTERESTS
More informationParkinson s Disease in the Elderly A Physicians perspective. Dr John Coyle
Parkinson s Disease in the Elderly A Physicians perspective Dr John Coyle Overview Introduction Epidemiology and aetiology Pathogenesis Diagnosis and clinical features Treatment Psychological issues/ non
More informationParkinson s disease. Information for patients and carers. The Leeds Teaching Hospitals NHS Trust
n The Leeds Teaching Hospitals NHS Trust Parkinson s disease Information for patients and carers in partnership with Leeds Community Healthcare NHS Trust The symptoms of Parkinson s appear when the levels
More informationOverview of Parkinson s disease Research at University of Colorado
Overview of Parkinson s disease Research at University of Colorado Brian D. Berman, MD, MS May 12, 2018 University of Colorado Movement Disorders Center Terminology Basic science pure/fundamental scientific
More informationNon-Motor Symptoms of Parkinson s Disease
Non-Motor Symptoms of Parkinson s Disease Samantha Holden, MD University of Colorado Movement Disorders MOTOR SYMPTOMS Rigidity Bradykinesia Tremor Gait Imbalance NON-MOTOR SYMPTOMS Dementia Urinary frequency
More information2-The age at onset of PD is variable, usually between 50 and 80 years, with a mean onset of 55 years (1).
Parkinson Disease 1-Parkinson disease (PD) is a chronic, progressive movement disorder resulting from loss of dopamine from the nigrostriatal tracts in the brain, and is characterized by rigidity, bradykinesia,
More informationParkinson s Disease Foundation. PD ExpertBriefing: Managing the Motor Symptoms in PD
Parkinson s Disease Foundation PD ExpertBriefing: Managing the Motor Symptoms in PD Led By: Sotirios A. Parashos, M.D. Minneapolis Clinic of Neurology and Struthers Parkinson's Center This session was
More informationPunit Agrawal, DO Clinical Assistant Professor of Neurology Division of Movement Disorders OSU Department of Neurology
Deep Brain Stimulation for Movement Disorders Punit Agrawal, DO Clinical Assistant Professor of Neurology Division of Movement Disorders OSU Department of Neurology History of DBS 1 History of DBS 1987
More informationUpdate on Parkinson s disease and other Movement Disorders October 2018
Update on Parkinson s disease and other Movement Disorders October 2018 DR. JONATHAN EVANS CONSULTANT IN NEUROLOGY QUEEN S MEDICAL CENTRE NOTTINGHAM Disclosures: Honoraria UCB, Britannia, Allergan, AbbVie
More informationUpdate in the Management of Parkinson s Disease
Update in the Management of Parkinson s Disease What s standard? What s new? What s coming? Bruno V. Gallo, M.D. Assistant Professor of Neurology, FIU Wertheim College of Medicine Director, Parkinson &
More informationMoving fast or moving slow: an overview of Movement Disorders
Moving fast or moving slow: an overview of Movement Disorders Mini Medical School October 25, 2018 Heather Rigby, MD, FRCPC 2014 MFMER slide-1 2014 MFMER slide-2 Basal Ganglia Dysfunction - Movement Disorders
More informationMultiple System Atrophy
Multiple System Atrophy This document has been prepared to help you become more informed about Multiple System Atrophy. It is designed to answer questions about the condition and includes suggestions on
More informationSurgical Treatment: Patient Edition
Parkinson s Disease Clinic and Research Center University of California, San Francisco 505 Parnassus Ave., Rm. 795-M, Box 0114 San Francisco, CA 94143-0114 (415) 476-9276 http://pdcenter.neurology.ucsf.edu
More informationASSFN Clinical Case: Bilateral STN DBS Implant for Parkinson s Disease
ASSFN Clinical Case: Bilateral STN DBS Implant for Parkinson s Disease Parkinson s Disease Cardinal Signs: Resting tremor Rigidity Bradykinesia Postural instability Other Symptoms Dystonia Dysphagia Autonomic
More informationParkinsons Disease update. Sindhu R Srivatsal MD MPH Virginia Mason Medical Center
Parkinsons Disease update Sindhu R Srivatsal MD MPH Virginia Mason Medical Center PARKINSONISM Vs PARKINSON S Parkinsonism Bradykinesia: slowness of movements (essential feature) PLUS one of Tremor: resting
More informationHistory Parkinson`s disease. Parkinson's disease was first formally described in 1817 by a London physician named James Parkinson
Parkinsonismm History Parkinson`s disease Parkinson's disease was first formally described in 1817 by a London physician named James Parkinson Definition : Parkinsonism: Parkinsonism is a progressive neurological
More informationParkinson s Disease. Patients will ask you. 8/14/2015. Objectives
Parkinson s Disease Jean Van Kingsley MS, FNP-BC Objectives Describe the pathophysiolgy of PD. Review clinical charachteristics of PD. Identify management strategies, to maximize functional status. Recognize
More informationChapter 20. Media Directory. Amyotrophic Lateral Sclerosis. Alzheimer s Disease. Huntington s Chorea. Multiple Sclerosis
Chapter 20 Drugs for Degenerative Diseases of the Nervous System Slide 18 Media Directory Levadopa Animation Upper Saddle River, New Jersey 07458 All rights reserved. Alzheimer s Disease Amyotrophic Lateral
More informationWhat You and Your Family Should Know
Parkinson s Disease: What You and Your Family Should Know Edited By: Gale Kittle, RN, MPH St. Joseph s Hospital and Medical Center Barrow Neurological Institute Pheonix, Arizona Your generosity makes this
More informationMotor Fluctuations in Parkinson s Disease
Motor Fluctuations in Parkinson s Disease Saeed Bohlega, MD, FRCPC Senior Distinguished Consultant Department of Neurosciences King Faisal Specialist Hospital & Research Centre Outline Type of fluctuations
More informationDrug Therapy of Parkinsonism. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Drug Therapy of Parkinsonism Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Parkinsonism is a progressive neurological disorder of muscle movement, usually
More informationEnhanced Primary Care Pathway: Parkinson s Disease
Enhanced Primary Care Pathway: Parkinson s Disease 1. Focused summary of PD relevant to primary care Parkinson s Disease (PD) and Essential tremor (ET) are two of the most common movement disorders encountered
More information